PRESS RELEASE published on 06/12/2025 at 22:42, 1 year 4 months ago Inside Information / Other news releases GeNeuro SA's French subsidiary GeNeuro Innovation SAS enters receivership proceedings amidst parent company's debt-restructuring efforts Autoimmune Diseases GeNeuro SA Neurodegenerative Diseases Debt-restructuring Receivership Proceedings
PRESS RELEASE published on 06/12/2025 at 22:42, 1 year 4 months ago Informations privilégiées / Autres communiqués GeNeuro annonce l’ouverture de la procédure de redressement judiciaire de sa filiale GeNeuro Innovation SAS. La société cherche à se restructurer pour surmonter ses difficultés financières Restructuration Difficultés Financières Redressement Judiciaire GeNeuro Sursis Concordataire
BRIEF published on 12/13/2024 at 12:02, 1 year 10 months ago Citigroup reduces its stake in GENEURO SA Euronext Paris Sale Of Shares Threshold Crossing GeNeuro SA Citigroup
BRIEF published on 12/13/2024 at 12:02, 1 year 10 months ago Citigroup réduit sa participation dans GENEURO SA Euronext Paris Franchissement De Seuil Vente D'actions GeNeuro SA Citigroup
PRESS RELEASE published on 12/13/2024 at 11:57, 1 year 10 months ago Franchissement de seuils Déclaration de franchissement de seuils de Citigroup Global Markets Limited concernant GENEURO SA publiée le 12 décembre 2024 Déclaration Franchissement De Seuils GeNeuro SA Citigroup Global Markets Limited
BRIEF published on 12/06/2024 at 18:35, 1 year 10 months ago GeNeuro dévoile son nouveau médicament de précision pour la SLA Médecine De Précision GeNeuro Traitement De La SLA GNK-301 ENVIRONNEMENT HERV-K
BRIEF published on 12/06/2024 at 18:35, 1 year 10 months ago GeNeuro's New Precision Medicine for ALS Unveiled Precision Medicine GeNeuro ALS Treatment GNK-301 HERV-K ENV
PRESS RELEASE published on 12/06/2024 at 18:30, 1 year 10 months ago Informations privilégiées / Autres communiqués Nouvelle approche de médecine de précision pour la SLA avec GNK-301 de GeNeuro présentée au 35e Symposium international sur la SLA/MMN Recherche Médecine De Précision GeNeuro SLA GNK-301
PRESS RELEASE published on 12/06/2024 at 18:30, 1 year 10 months ago Inside Information / Other news releases GeNeuro presents groundbreaking findings on precision medicine for ALS patients with GNK-301 at the 35th International Symposium on ALS/MND. Research highlights potential of targeting HERV-K ENV to transform ALS treatment Precision Medicine ALS GeNeuro GNK-301 HERV-K ENV
BRIEF published on 11/06/2024 at 09:48, 1 year 11 months ago Crossing of thresholds by Invus Public Equities in GENEURO SA Euronext Paris Capital Increase Crossing Thresholds GeNeuro SA Invus Public Equities
Published on 10/28/2026 at 02:55, 1 hour 19 minutes ago Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 1 hour 24 minutes ago Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 4 hours 34 minutes ago Second Closing of US$3.4 Million Private Placement
Published on 10/27/2026 at 23:25, 4 hours 49 minutes ago Gamma Resources Announces Leadership Transition: C. Connor Messler to Become Chief Executive Officer and Gabriel Alonso-Mendoza to Become Chairman; Grants Incentive Stock Options
Published on 10/27/2026 at 21:30, 6 hours 44 minutes ago Apex Announces Closing of Over-Allotment Option
Published on 10/28/2026 at 02:25, 1 hour 49 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: 2026 AGM Chair and Group CEO address
Published on 10/28/2026 at 02:19, 1 hour 55 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: September 2026 quarter update
Published on 10/27/2026 at 22:40, 5 hours 34 minutes ago EQS-Adhoc: NEXTDC Limited: Financial Covenants - Compliance and Headroom
Published on 10/27/2026 at 22:30, 5 hours 44 minutes ago Tensor and Münchner Taxi Zentrum Sign LOI to Put Taxi Operators at the Center of Autonomous Mobility in Germany
Published on 10/27/2026 at 20:35, 7 hours 39 minutes ago Piramal Pharma Limited Announces Results for Q2 and H1 FY27
Published on 10/27/2026 at 18:00, 10 hours 14 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 10 hours 14 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
